RNAZ Key Statistics, Chart & Performance
The current stock price of RNAZ is 10.5 USD. In the past month the price increased by 16.58%. In the past year, price decreased by -96.89%.
RNAZ Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to RNAZ. When comparing the yearly performance of all stocks, RNAZ is a bad performer in the overall market: 95.3% of all stocks are doing better.
RNAZ Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to RNAZ. RNAZ scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
RNAZ Financial Highlights
Over the last trailing twelve months RNAZ reported a non-GAAP Earnings per Share(EPS) of -1462.72. The EPS increased by 95.47% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -519.73% | ||
| ROE | -1904.95% | ||
| Debt/Equity | 0 |
RNAZ Forecast & Estimates
For the next year, analysts expect an EPS growth of 99.7% and a revenue growth -100% for RNAZ
RNAZ Ownership
RNAZ Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.05 | 383.716B | ||
| AMGN | AMGEN INC | 16.25 | 197.191B | ||
| GILD | GILEAD SCIENCES INC | 16.74 | 181.425B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.52 | 119.38B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.66 | 81.459B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.29 | 46.497B | ||
| INSM | INSMED INC | N/A | 32.511B | ||
| NTRA | NATERA INC | N/A | 28.376B | ||
| BIIB | BIOGEN INC | 12.02 | 27.206B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.25 | 20.78B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About RNAZ
Company Profile
TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company is headquartered in Boston, Massachusetts and currently employs 7 full-time employees. The company went IPO on 2021-04-28. The company is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The firm is also developing a portfolio of RNA therapeutic candidates to overcome delivery challenges and unlock access to novel genetic targets. Its preclinical programs include TTX-siPDL1 (siRNA modulator of PD-L1), TTX-RIGA (RNA agonist of RIG-I for innate immunity activation), and TTX-siMYC (siRNA inhibitor of c-MYC). Additionally, R&D efforts are exploring the combination of TTX-MC138 and seviprotimut-L technologies to enhance therapeutic impact.
Company Info
TRANSCODE THERAPEUTICS INC
6 Liberty Square, #2382
Boston MASSACHUSETTS US
CEO: Robert Michael Dudley
Employees: 7
Phone: 18573016857
TRANSCODE THERAPEUTICS INC / RNAZ FAQ
What does TRANSCODE THERAPEUTICS INC do?
TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company is headquartered in Boston, Massachusetts and currently employs 7 full-time employees. The company went IPO on 2021-04-28. The company is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The firm is also developing a portfolio of RNA therapeutic candidates to overcome delivery challenges and unlock access to novel genetic targets. Its preclinical programs include TTX-siPDL1 (siRNA modulator of PD-L1), TTX-RIGA (RNA agonist of RIG-I for innate immunity activation), and TTX-siMYC (siRNA inhibitor of c-MYC). Additionally, R&D efforts are exploring the combination of TTX-MC138 and seviprotimut-L technologies to enhance therapeutic impact.
What is the current price of RNAZ stock?
The current stock price of RNAZ is 10.5 USD. The price increased by 22.38% in the last trading session.
Does RNAZ stock pay dividends?
RNAZ does not pay a dividend.
What is the ChartMill technical and fundamental rating of RNAZ stock?
RNAZ has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the PE ratio for RNAZ stock?
TRANSCODE THERAPEUTICS INC (RNAZ) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1462.72).
What is the employee count for RNAZ stock?
TRANSCODE THERAPEUTICS INC (RNAZ) currently has 7 employees.